Coloplast As Stock Net Income
| CBHD Stock | EUR 65.64 1.40 2.18% |
As of the 24th of February, Coloplast shows the Risk Adjusted Performance of (0.01), standard deviation of 4.64, and Mean Deviation of 1.99. Coloplast AS technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm Coloplast AS treynor ratio, value at risk, and the relationship between the information ratio and maximum drawdown to decide if Coloplast AS is priced correctly, providing market reflects its regular price of 65.64 per share.
Coloplast Total Revenue |
|
Gross Profit | Profit Margin | Market Capitalization 14.5 B | Enterprise Value Revenue 5.4575 | Revenue |
| Last Reported | Projected for Next Year | ||
| Net Income From Continuing Ops | 5.8 B | 4.2 B | |
| Net Income Applicable To Common Shares | 5.4 B | 3.9 B | |
| Net Income | 5.8 B | 4.2 B |
Coloplast | Net Income |
The Net Income trend for Coloplast AS offers valuable insights into the company's financial trajectory and strategic direction. By examining multi-year patterns, investors can identify whether Coloplast is strengthening or weakening its position, and how this metric correlates with broader market conditions and industry benchmarks.
Latest Coloplast's Net Income Growth Pattern
Below is the plot of the Net Income of Coloplast AS over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Coloplast AS financial statement analysis. It represents the amount of money remaining after all of Coloplast AS operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Coloplast's Net Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Coloplast's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported 5.05 B | 10 Years Trend |
|
Net Income |
| Timeline |
Coloplast Net Income Regression Statistics
| Arithmetic Mean | 3,746,635,294 | |
| Geometric Mean | 3,460,382,259 | |
| Coefficient Of Variation | 34.71 | |
| Mean Deviation | 1,044,448,443 | |
| Median | 3,873,000,000 | |
| Standard Deviation | 1,300,280,368 | |
| Sample Variance | 1690729T | |
| Range | 4.9B | |
| R-Value | 0.86 | |
| Mean Square Error | 481632T | |
| R-Squared | 0.73 | |
| Significance | 0.000012 | |
| Slope | 220,445,098 | |
| Total Sum of Squares | 27051664.6T |
Coloplast Net Income History
Coloplast 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Coloplast's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Coloplast.
| 11/26/2025 |
| 02/24/2026 |
If you would invest 0.00 in Coloplast on November 26, 2025 and sell it all today you would earn a total of 0.00 from holding Coloplast AS or generate 0.0% return on investment in Coloplast over 90 days. Coloplast is related to or competes with Cerence, TELES Informationstech, BIOTIME, MBIA, MBIA, Tsodilo Resources, and ANGES MG. Coloplast AS develops and markets intimate healthcare products and services worldwide More
Coloplast Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Coloplast's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Coloplast AS upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.05) | |||
| Maximum Drawdown | 36.1 | |||
| Value At Risk | (4.10) | |||
| Potential Upside | 3.08 |
Coloplast Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Coloplast's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Coloplast's standard deviation. In reality, there are many statistical measures that can use Coloplast historical prices to predict the future Coloplast's volatility.| Risk Adjusted Performance | (0.01) | |||
| Jensen Alpha | (0.09) | |||
| Total Risk Alpha | (0.68) | |||
| Treynor Ratio | 0.3814 |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Coloplast's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Coloplast February 24, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.01) | |||
| Market Risk Adjusted Performance | 0.3914 | |||
| Mean Deviation | 1.99 | |||
| Coefficient Of Variation | (4,054) | |||
| Standard Deviation | 4.64 | |||
| Variance | 21.56 | |||
| Information Ratio | (0.05) | |||
| Jensen Alpha | (0.09) | |||
| Total Risk Alpha | (0.68) | |||
| Treynor Ratio | 0.3814 | |||
| Maximum Drawdown | 36.1 | |||
| Value At Risk | (4.10) | |||
| Potential Upside | 3.08 | |||
| Skewness | 2.03 | |||
| Kurtosis | 24.46 |
Coloplast AS Backtested Returns
Coloplast AS secures Sharpe Ratio (or Efficiency) of -0.0248, which signifies that the company had a -0.0248 % return per unit of risk over the last 3 months. Coloplast AS exposes twenty-four different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm Coloplast's Standard Deviation of 4.64, mean deviation of 1.99, and Risk Adjusted Performance of (0.01) to double-check the risk estimate we provide. The firm shows a Beta (market volatility) of -0.33, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Coloplast are expected to decrease at a much lower rate. During the bear market, Coloplast is likely to outperform the market. At this point, Coloplast AS has a negative expected return of -0.12%. Please make sure to confirm Coloplast's jensen alpha, treynor ratio, value at risk, as well as the relationship between the total risk alpha and maximum drawdown , to decide if Coloplast AS performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.15 |
Insignificant predictability
Coloplast AS has insignificant predictability. Overlapping area represents the amount of predictability between Coloplast time series from 26th of November 2025 to 10th of January 2026 and 10th of January 2026 to 24th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Coloplast AS price movement. The serial correlation of 0.15 indicates that less than 15.0% of current Coloplast price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.15 | |
| Spearman Rank Test | 0.32 | |
| Residual Average | 0.0 | |
| Price Variance | 17.24 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Coloplast Operating Income
Operating Income |
|
Based on the recorded statements, Coloplast AS reported net income of 5.05 B. This is much higher than that of the Health Care Equipment & Supplies sector and significantly higher than that of the Health Care industry. The net income for all Germany stocks is significantly lower than that of the firm.
Coloplast Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Coloplast's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Coloplast could also be used in its relative valuation, which is a method of valuing Coloplast by comparing valuation metrics of similar companies.Coloplast is currently under evaluation in net income category among its peers.
Coloplast ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Coloplast's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Coloplast's managers, analysts, and investors.Environment Score | Governance Score | Social Score |
Coloplast Fundamentals
| Return On Equity | 0.27 | ||||
| Return On Asset | 0.0985 | ||||
| Profit Margin | 0.14 % | ||||
| Operating Margin | 0.26 % | ||||
| Current Valuation | 20.46 B | ||||
| Shares Outstanding | 207.37 M | ||||
| Shares Owned By Insiders | 29.79 % | ||||
| Shares Owned By Institutions | 28.94 % | ||||
| Price To Earning | 38.18 X | ||||
| Price To Book | 7.87 X | ||||
| Price To Sales | 0.52 X | ||||
| Revenue | 27.03 B | ||||
| Gross Profit | 18.93 B | ||||
| EBITDA | 8.58 B | ||||
| Net Income | 5.05 B | ||||
| Cash And Equivalents | 143.67 M | ||||
| Cash Per Share | 0.68 X | ||||
| Total Debt | 5.08 B | ||||
| Debt To Equity | 43.40 % | ||||
| Current Ratio | 1.12 X | ||||
| Book Value Per Share | 8.21 X | ||||
| Cash Flow From Operations | 2.77 B | ||||
| Earnings Per Share | 2.37 X | ||||
| Price To Earnings To Growth | 2.26 X | ||||
| Target Price | 19.05 | ||||
| Number Of Employees | 16.98 K | ||||
| Beta | 0.59 | ||||
| Market Capitalization | 14.48 B | ||||
| Total Asset | 48.07 B | ||||
| Retained Earnings | 15.39 B | ||||
| Working Capital | 240 M | ||||
| Annual Yield | 0.05 % | ||||
| Five Year Return | 2.47 % | ||||
| Net Asset | 48.07 B | ||||
| Last Dividend Paid | 23.0 |
About Coloplast Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Coloplast AS's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Coloplast using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Coloplast AS based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Other Information on Investing in Coloplast Stock
Coloplast financial ratios help investors to determine whether Coloplast Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Coloplast with respect to the benefits of owning Coloplast security.